How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
Abstract Background Migraine is a major public health issue associated with significant morbidity, considerable negative impact on quality of life, and significant socioeconomic burden. Preventive treatments are required to reduce the occurrence and the severity of acute attacks and to minimize the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Series: | The Journal of Headache and Pain |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s10194-019-1000-5 |
| _version_ | 1811294954773807104 |
|---|---|
| author | Cindy Tiseo Raffaele Ornello Francesca Pistoia Simona Sacco |
| author_facet | Cindy Tiseo Raffaele Ornello Francesca Pistoia Simona Sacco |
| author_sort | Cindy Tiseo |
| collection | DOAJ |
| description | Abstract Background Migraine is a major public health issue associated with significant morbidity, considerable negative impact on quality of life, and significant socioeconomic burden. Preventive treatments are required to reduce the occurrence and the severity of acute attacks and to minimize the use of abortive medications and the associate risk of drug-related adverse events, as well as the onset of medication-overuse headache and chronification of migraine. We performed a review of all available evidence on the safety and efficacy of monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor for the preventive treatment of migraine to provide evidence-based guidance on their use in clinical practice. Abstract main body Monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor are mechanism-specific drugs for the preventive treatment of migraine. Double-blind randomized clinical trials have shown that monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor are effective across all the spectrum of migraine patients who require prevention and have a good safety and tolerability profile. Nevertheless, high costs limit the affordability of those drugs at the moment. Conclusions Specificity, long half-life, efficacy, tolerability, and ease of use make monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor an appealing treatment option for migraine prevention. Optimal strategies to manage treatment over time still need to be clarified with real-life data. |
| first_indexed | 2024-04-13T05:25:13Z |
| format | Article |
| id | doaj.art-e887c9bc121540ed9bdfa2a0a7ed39c6 |
| institution | Directory Open Access Journal |
| issn | 1129-2369 1129-2377 |
| language | English |
| last_indexed | 2024-04-13T05:25:13Z |
| publishDate | 2019-05-01 |
| publisher | BMC |
| record_format | Article |
| series | The Journal of Headache and Pain |
| spelling | doaj.art-e887c9bc121540ed9bdfa2a0a7ed39c62022-12-22T03:00:36ZengBMCThe Journal of Headache and Pain1129-23691129-23772019-05-0120111310.1186/s10194-019-1000-5How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practiceCindy Tiseo0Raffaele Ornello1Francesca Pistoia2Simona Sacco3Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’AquilaNeuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’AquilaNeuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’AquilaNeuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’AquilaAbstract Background Migraine is a major public health issue associated with significant morbidity, considerable negative impact on quality of life, and significant socioeconomic burden. Preventive treatments are required to reduce the occurrence and the severity of acute attacks and to minimize the use of abortive medications and the associate risk of drug-related adverse events, as well as the onset of medication-overuse headache and chronification of migraine. We performed a review of all available evidence on the safety and efficacy of monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor for the preventive treatment of migraine to provide evidence-based guidance on their use in clinical practice. Abstract main body Monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor are mechanism-specific drugs for the preventive treatment of migraine. Double-blind randomized clinical trials have shown that monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor are effective across all the spectrum of migraine patients who require prevention and have a good safety and tolerability profile. Nevertheless, high costs limit the affordability of those drugs at the moment. Conclusions Specificity, long half-life, efficacy, tolerability, and ease of use make monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor an appealing treatment option for migraine prevention. Optimal strategies to manage treatment over time still need to be clarified with real-life data.http://link.springer.com/article/10.1186/s10194-019-1000-5MigraineCalcitonin gene-related peptidePreventive treatmentMonoclonal antibodies |
| spellingShingle | Cindy Tiseo Raffaele Ornello Francesca Pistoia Simona Sacco How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice The Journal of Headache and Pain Migraine Calcitonin gene-related peptide Preventive treatment Monoclonal antibodies |
| title | How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice |
| title_full | How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice |
| title_fullStr | How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice |
| title_full_unstemmed | How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice |
| title_short | How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice |
| title_sort | how to integrate monoclonal antibodies targeting the calcitonin gene related peptide or its receptor in daily clinical practice |
| topic | Migraine Calcitonin gene-related peptide Preventive treatment Monoclonal antibodies |
| url | http://link.springer.com/article/10.1186/s10194-019-1000-5 |
| work_keys_str_mv | AT cindytiseo howtointegratemonoclonalantibodiestargetingthecalcitoningenerelatedpeptideoritsreceptorindailyclinicalpractice AT raffaeleornello howtointegratemonoclonalantibodiestargetingthecalcitoningenerelatedpeptideoritsreceptorindailyclinicalpractice AT francescapistoia howtointegratemonoclonalantibodiestargetingthecalcitoningenerelatedpeptideoritsreceptorindailyclinicalpractice AT simonasacco howtointegratemonoclonalantibodiestargetingthecalcitoningenerelatedpeptideoritsreceptorindailyclinicalpractice |